Page 26 - டைமாஸ் கோவாஸ் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

SE (“Valneva” or “the Company”), a specialty vaccine company focused on prevention of infectious diseases with significant unmet medical need, and Instituto Butantan, producer of immunobiologic products, today announced the signing of definitive agreements for the development, manufacturing and marketing of Valneva’s single-shot chikungunya vaccine, VLA1553, in Low and Middle Income Countries (LMICs). This finalization follows the signing of a binding term sheet in May 2020 1.  The collaboration falls within the framework of the $23.4 million funding agreement Valneva signed with the Coalition for Epidemic Preparedness Innovations (CEPI) in July 2019 2. Under the collaboration, Valneva will transfer its chikungunya vaccine technology to Instituto Butantan, who will develop, manufacture and commercialize the vaccine in LMICs. In addition, Instituto Butantan will provide certain clinical and Phase 4 observational studies that Valneva will use to meet regulatory requireme

Sao pauloUnited kingdomDimas covasMelanie savilleTeresa pinzolitsInstituto butantanThomas lingelbachBrazilian ministry of healthButantan instituteCorporate communications specialistWorld health organizationDrug administrationMelinda gates foundationUnited nationsCoalition for epidemic preparedness innovationsWorld health organisation